[1]Benishin C G. 1992. Actions of ginsenoside Rb1 on choline uptake in central cholinergic nerve endings. Neurochemistry International, 21, 1-5. [2]Borsini F, Volterra G, Meli A. 1986. Does the behavioral ‘despair’ test measure ‘despair’. Physiology and Behavior, 38, 385-386. [3]Butterweck V, Bockers T, Korte B, Bittkowski W, Winterhoff H. 2002. Long-term effects of St. John’s wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Research, 930, 21-29. [4]Campos M M, Fernandes E S, Ferreira J, Bortolanza L B, Santos A R, Calixto J B. 2004. Pharmacological and neurochemical evidence for antidepressant like effects of the herbal product Catuama. Pharmacology, Biochemistry, and Behavior, 78, 757-764. [5]Commissiong J W. 1985. Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochemical Pharmacology, 34, 1127-1131. [6]Dang H, Chen Y, Liu X, Wang Q, Wang L, Jia W, Wang Y. 2009. Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 1417-1424. [7]D’Aquila P A, Collu M, Gessa G L, Serra G. 2000. The role of dopamine in the mechanism of action of antidepressant drugs. European Journal of Pharmacology, 405, 365-373. [8]Duman R S, Heninger G R, Nestler E J. 1997. A molecular and cellular theory of depression. Archives of General Psychiatry, 54, 597-606. [9]Feng L J, Huang L, Zhuo H Q, Huang H Q. 2008. Differential proteins of Panax Notoginseng powder inducement identified and analyzed with proteomic techniques in neural connective of Aplysia. Chinese Journal of Applied Chemistry, 36, 577-582. [10]Gillis C N. 1997. Panax ginseng pharmacology: a nitric oxide link? Biochemical Pharmacology, 54, 1-8. [11]Harro J, Tonissaar M, Eller M, Kask A, Oreland L. 2001. Chronic variable stress and partial 5-HT denervation by parachloroamphetamine treatment in the rat: effects on behavior and monoamine neurochemistry. Brain Research, 899, 227-239. [12]Nemeroff C B. 2007. The burden of severe depression: A review of diagnostic challenges and treatment alternatives. Journal of Psychiatrion Research, 41, 189-206. [13]Nitta A, Furukawa Y, Hayashi K, Hiramatsu M, Kameyama T, Hasegawa T, Nabeshima T. 1992. Denervation of dopaminergic neurons with 6-hydroxydopamine increases nerve growth factor content in rat brain. Neuroscience Letters, 144, 152-156. [14]Paxinos G, Franklin K B J. 1997. The Mouse Brain in Stereotaxic Coordinates (Chapter 2). Academic Press, San Diego. Petty F, Triyedi M H, Fulton M, Rush A J. 1995. Benzodiazepines as antidepressants: does GABA play a role in depression? Biological Psychiatry, 38, 578-591. [15]Poirier M F, Boyer P. 1999. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomized comparison. The British Journal of Psychiatry, 175, 12-16. [16]Porsolt R D, Bertin A, Jalfre M. 1977. Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Thérapie, 229, 327-336. [17]Rasheed N, Tyagi E, Ahmad A, Siripurapu K B, Lahiri S, Shukla R, Palit G. 2008. Involvement of monoamines and proinflammatory cytokines in mediating the antistress effects of Panax quinquefolium. Journal of Ethnopharmacology, 117, 257-262. [18]Rosenzweig-Lipson S, Beyer C E, Hughes Z A, Khawaja X, Rajarao S J, Malberg J E, Rahman Z, Ring R H, Schechter L E. 2007. Differentiating antidepressants of the future: Efficacy and safety. Pharmacology and Therapeutics, 113, 134-153. [19]Schwarting R K, Huston J P. 1992. Behavioral concomitants of regional changes in the brain’s biogenic amines after apomorphine and amphetamine. Pharmacology, Biochemistry and Behavior, 41, 675-682. [20]Stahl S M. 1998. Basic psychopharmacology of antidepressants, Part 1: antidepressants have seven distinct mechanisms of action. The Journal of Clinical Psychiatry, 59, 5-14. [21]Steru L, Chermat R, Thierry B, Simon P. 1985. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology, 85, 367-370. [22]Thachil A F, Mohan R, Bhugra D. 2007. The evidence base of complementary and alternative therapies in depression. Journal of Affective Disorders, 97, 23-35. [23]Tsang D, Yeung H W, Tso W W, Peck H. 1985. Ginseng saponins: Influence on neurotransmitters uptake in rat brain synaptosomes. Planta Medica, 51, 221-224. [24]Willner P. Animal models as stimulations of depression. 1991. Trends in Pharmacological Sciences, 12, 131-136. |